Navigation Links
Indevus Announces Allergan as New Partner for SANCTURA Brand
Date:9/19/2007

p>

Except for the descriptions of historical facts contained herein, this press release contains forward-looking statements that involve risks and uncertainties that could cause the Company's actual results and financial condition to differ materially from those anticipated by the forward-looking statements. These risks and uncertainties are set forth in the Company's filings under the Securities Act of 1933 and the Securities Exchange Act of 1934 under "Risk Factors" and elsewhere, and include, but are not limited to: dependence on the success of SANCTURA(R), SANCTURA(R) XR, NEBIDO(R), VANTAS(R) and SUPPRELIN(R) LA; the early state of products under development; uncertainties relating to clinical trials, regulatory approval and commercialization of our products, particularly SANCTURA XR, NEBIDO, and VALSTAR(R); risks associated with contractual agreements, particularly for the manufacture and co-promotion of SANCTURA and SANCTURA XR and the manufacture of NEBIDO, VANTAS, SUPPRELIN LA and VALSTAR; dependence on third parties for supplies, particularly for histrelin, manufacturing, marketing, and clinical trials; competition; need for additional funds and corporate partners, including for the development of our products; failure to acquire and develop additional product candidates; changes in reimbursement policies and/or rates for SANCTURA, VANTAS, SUPPRELIN LA, DELATESTRYL(R) and any future products; history of operating losses and expectation of future losses; product liability and insurance uncertainties; risks relating to the Redux- related litigation; the risk that the businesses of Indevus and Valera Pharmaceuticals, Inc. will not be integrated successfully during the period following the related merger; the risk that the cost savings and any other synergies from the merger may not be fully realized or may take longer to realize than expected; market acceptance for the merger and approved products; risks of regulatory review and clinical trials; disruption f
'/>"/>

SOURCE Indevus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... NEWPORT BEACH, Calif. , July 28, 2015 ... company, announced that it has hit a milestone ... Putty. Signafuse was FDA 510(k) cleared in early ... standalone use in posterolateral spine fusion procedures.  This ... graft products, as less than 6% of new ...
(Date:7/28/2015)... Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 ... today announced its financial results for the second ...  sales grew nearly 300% as compared to the ... first launched," said Roger Jeffs, Ph.D., United Therapeutics, ... Orenitram sales was due to an increase in ...
(Date:7/27/2015)... OAKS, Calif. , July 27, 2015  Amgen ... report its second quarter financial results on Thursday, July ... markets. The announcement will be followed by a conference ... Participating in the call from Amgen will be ... and other members of Amgen,s senior management team. ...
(Date:7/27/2015)... ... 2015 , ... This is a professional and in-depth study ... of the industry including definitions, classifications, applications and industry chain structure. The Biophotonics ... analysis, and key regions development status. Development policies and plans are discussed as ...
Breaking Biology Technology:Revolutionary Bone Graft Exceeds Expectations 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11Amgen Announces Webcast of 2015 Second Quarter Financial Results 22015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3
... (Amex: CPD ) announced the resignation as a ... appointment as a Director of the,Company of Gurpartap ("GP") ... the Company, effective July 22, 2008., Prior to ... July 2007, Mr. Singh served as Vice President - ...
... new CEO,Andrew Witty comments on GSK,s second quarter results while ... The new strategic priorities for GlaxoSmithKline ... Deliver more products of value - Simplify GSK,s operating ... on, http://www.cantos.com . It,s free to view. All you need ...
... retraction needed for surgical ... ... the market availability of the SlimFuse(TM) Anterior,Cervical Plate System. This innovative ... clinical needs of,anterior cervical discectomy and fusion (ACDF) surgery., SlimFuse(TM) ...
Cached Biology Technology:Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva 2Pioneer(R) Surgical Technology, Inc. Announces the Market Launch of the SlimFuse(TM) Anterior Cervical Plate System 2
(Date:7/7/2015)... , July 7, 2015  Based on its ... & Sullivan recognizes Credence ID, LLC with the ... Company of the Year Award. Credence ID has ... in its mission of offering enrollment and identification ... As Credence ID was formed by experts from ...
(Date:6/30/2015)... June 30, 2015 To bolster its efforts and ... Corp. announced today the addition of two new team members. ... board advisor and David Raviv will act as ... HYPR Corp.,s commitment to providing the most secure solutions for ... co-founded Layer 7 Technologies, a provider of security and ...
(Date:6/25/2015)... 2015  Imagine a tool specifically designed to help ... life. That,s exactly what USANA,s True Health Assessment ... portable health program provides a personalized approached to measuring ... your lifestyle and nutrition. At the ... night, USANA,s THA was honored with the Industry Innovation ...
Breaking Biology News(10 mins):Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 2Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 3Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 4Frost & Sullivan Acknowledges the Distinctive Customer-focused Attributes of Credence ID's Mobile Biometric Product Suite 5HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... ductal adenocarcinoma is an almost uniformly fatal disease regardless ... small percentage of patients develop a form of ductal ... earlier, is less aggressive and has a 50 percent ... differently, despite carrying the same basic genetic mutations as ...
... the University of Rochester Biomedical Engineering Department has invented ... stem cells. When he captures cancer cells, he ... harvests them for later use in tissue engineering, bone ... and improve health. With Nichola Charles, Jared Kanofsky, ...
... year to the UK poultry industry but scientists are now ... ?one that can be delivered while they are still in ... provides immunity to IBV has been developed by scientists at ... UK. It can be delivered to chicks still in the ...
Cached Biology News:Genetic pathways to curable and incurable forms of pancreatic cancer identified 2Genetic pathways to curable and incurable forms of pancreatic cancer identified 3Cancer-killing invention also harvests stem cells 2Cancer-killing invention also harvests stem cells 3Cancer-killing invention also harvests stem cells 4In-shell vaccine for chick disease 2
Adhesion Molecule Antibodies...
Goat polyclonal to Factor VIII, prediluted ( Abpromise for all tested applications). Antigen: Full length native protein (purified) (Human): Factor VIII from blood. Entrez GeneID: 2157 Sw...
Affinity Purified Rabbit Anti-mouse sRANKL Biotinylated Polyclonal Antibody...
... been reported in heart tissues, and ... cell culture conditions. Treatment of ... production of TIMP-4 in some cell ... produced often require concentration of cell ...
Biology Products: